Scirica (USA) Jindrich Spinar Lee Kaplan Andrzej Budaj (Poland) Jose Carlos Nicolau Kausik Rayĥ Trial Schema Lorcaserin PLACEBO 10mg BID N = 12,000 Wiviott (USA) Ton Oude Ophuis Ramon Corbalan Lawrence A. White (New Zealand) Jamie Dwyer Mikhail Ruda Anthony Keech (Australia) Armando Garcia-Castillo (Mex) Christian Hamm Neil Weissman Milan Gupta (Canada) Stephen D. Magnus Ohman (Chair) Pamela Douglas Giles Montalescot Bernard Zinman Sheryl Kelsey (Stats) Steering Committee & National Lead Investigators (NLI) Conville Brown (Bahamas) Harvey D. Bonaca (Safety Chair) Polly Fish (Director of Ops) Julia Kuder Alexan Pricken Sabina Murphy (Director of Stats) Kelly Im (Assoc Dir Stats)Ğstella Kanevskyĝan Gabovitch Sponsor: Eisai Tushar Patelěruce Francis Wenfeng MiaoĜarlos Perdomo Independent Data Monitoring Committee E. Bohula (Investigator)Ĝhristian Ruff (CEC Chair)Ĝheryl Lowe Tim Abrahamsen Marc P. Wiviott (Co-PI) Silvio Inzucchi Steven R. Hypothalamic activation of the POMC (pro-opiomelanocortin) pathway → appetite suppression Based on phase 3 studies testing weight loss efficacy, approved for use in the US for chronic weight management + 5HT2CR Lorcaserin Image modified from Marx J. Sabatine on behalf of the CAMELLIA-TIMI 61 InvestigatorsĢ Weight Loss Agents Weight loss can improve CV risk factors, but is difficult to achieve and maintain Weight loss agents are guideline-recommended adjuncts to lifestyle modification1, 2 However, no agent has convincingly demonstrated CV safety in a rigorous clinical outcomes study In fact, several agents have been shown to precipitate CV or psychiatric side effects US FDA mandate to demonstrate CV safety for all weight loss agents 12013 AHA/ACC/TOS Guideline, Circulation 2014 129:S102 22014 AACE/ACE Position Statement, Endocr Pract 2014 20:977ģ Lorcaserin Selective agonist of serotonin (5HT)-2C receptor Presentation on theme: "on behalf of the CAMELLIA-TIMI 61 Investigators"- Presentation transcript:ġ on behalf of the CAMELLIA-TIMI 61 InvestigatorsĬardiovascular safety & efficacy of lorcaserin in overweight and obese patients Primary results from the CAMELLIA- TIMI 61 Trial E.A.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |